AR035534A1 - Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion - Google Patents

Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion

Info

Publication number
AR035534A1
AR035534A1 ARP020100289A ARP020100289A AR035534A1 AR 035534 A1 AR035534 A1 AR 035534A1 AR P020100289 A ARP020100289 A AR P020100289A AR P020100289 A ARP020100289 A AR P020100289A AR 035534 A1 AR035534 A1 AR 035534A1
Authority
AR
Argentina
Prior art keywords
seq
cell
plant
polyunsaturated fatty
vegetable
Prior art date
Application number
ARP020100289A
Other languages
English (en)
Inventor
Pradip Mukerji
Yung-Sheng Huang
Tapas Das
Jennifer Thurmond
Suzette L Pereira
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR035534A1 publication Critical patent/AR035534A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6431—Linoleic acids [18:2[n-6]]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)

Abstract

Secuencia de nucleótidos aislada, o fragmento, que comprende o que es complementaria en por lo menos un 50% aproximadamente de la secuencia de nucleótidos que comprende la SEQ ID N° 13, la SEQ ID N° 19 o la SEQ ID N° 28, SEQ ID N° 30, SEQ ID N° 32 o SEQ ID N° 34. Estas secuencias pueden codificar una desaturasa funcionalmente activa (proteína purificada) que utiliza un ácido graso poliinsaturado como sustrato. Las secuencias pueden derivar, de Saprolegnia diclina (SEQ ID N° 13 y SEQ ID N° 19), Thraustochytrium aureum (SEQ ID N° 28, SEQ ID N° 30 y SEQ ID N° 32) o de Isochysis galbana (SEQ ID N° 34). Además se incluyen las proteínas purificadas codificadas por las secuencias de nucleótidos a las que se hizo referencia previamente. Aún más, también se revela un método para producir una desaturasa. También se describe un vector que comprende la secuencia de nucleótidos representada en la SEQ ID N° 13, SEQ ID N° 19, SEQ ID N° 28, SEQ ID N° 30, SEQ ID N° 32 o SEQ ID N° 34 ligada operativamente a una secuencia promotora o reguladora. Una célula huésped, una célula de mamífero, una célula vegetal, una planta, un tejido vegetal o una planta transgénica que comprendan este vector, también se detallan así como los ácidos o aceites que se expresan. Además, se incluye un método para producir un ácido graso poliinsaturado así como una composición nutricional que comprende por lo menos un ácido graso poliinsaturado seleccionado del grupo formado por el producto de ácido graso poliinsaturado producido de acuerdo con los métodos descriptos previamente. Las desaturasas son criticas para la producción de ácidos grasos poliinsaturados de cadena larga (PUFA) que cumplen muchas funciones importantes como por ejemplo en la membrana plasmática de una célula, donde se encuentran en la forma de fosfolípidos. Resulta de interés aislar los genes involucrados en la síntesis de PUFA provenientes de especies que producen éstos ácidos grasos de forma natural y expresar dichos genes en un sistema microbiológico, vegetal o animal que pueda ser alterado para proveer la producción de cantidades comerciales de uno o varios PUFA.
ARP020100289A 2001-01-25 2002-01-25 Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion AR035534A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/769,863 US6635451B2 (en) 2001-01-25 2001-01-25 Desaturase genes and uses thereof
US10/054,534 US7067285B2 (en) 2001-01-25 2002-01-22 Desaturase genes and uses thereof

Publications (1)

Publication Number Publication Date
AR035534A1 true AR035534A1 (es) 2004-06-02

Family

ID=27735000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100289A AR035534A1 (es) 2001-01-25 2002-01-25 Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion

Country Status (8)

Country Link
US (6) US6635451B2 (es)
EP (2) EP2333052B1 (es)
JP (3) JP4347397B2 (es)
AR (1) AR035534A1 (es)
AT (1) ATE535602T1 (es)
CA (2) CA2698579C (es)
ES (1) ES2377198T3 (es)
PT (1) PT1392823E (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635451B2 (en) * 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
US20050089879A1 (en) * 2001-07-31 2005-04-28 Ivo Feussner Method for producing arachidonic acid in transgenic organisms
DE10219203A1 (de) * 2002-04-29 2003-11-13 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in Pflanzen
CA2518197A1 (en) * 2003-03-07 2004-09-23 Advanced Bionutrition Corporation Feed formulation for terrestrial and aquatic animals
ES2323644T3 (es) 2003-08-21 2009-07-22 Monsanto Technology Llc Desaturasas de acidos grasos procedentes de primula.
US8378186B2 (en) 2004-04-16 2013-02-19 Monsanto Technology Llc Expression of fatty acid desaturases in corn
US7807849B2 (en) 2004-04-22 2010-10-05 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
CA3023314C (en) 2004-04-22 2019-12-10 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
AU2011232757B2 (en) * 2004-04-22 2013-10-03 Commonwealth Scientific And Industrial Research Organisation Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
US7364883B2 (en) * 2004-05-07 2008-04-29 Yeastern Biotech Co., Ltd. Process for producing poly-unsaturated fatty acids by oleaginous yeasts
WO2005118814A2 (en) * 2004-06-04 2005-12-15 Fluxome Sciences A/S Metabolically engineered cells for the production of polyunsaturated fatty acids
US7588931B2 (en) * 2004-11-04 2009-09-15 E. I. Du Pont De Nemours And Company High arachidonic acid producing strains of Yarrowia lipolytica
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
BRPI0608637A2 (pt) 2005-03-16 2010-01-19 Metabolix Inc vetor recombinante para expressço de enzimas, cÉlula de planta transformada, mÉtodo para produÇço de produto biossintÉtico
JP5033122B2 (ja) 2005-05-23 2012-09-26 アルカディア バイオサイエンシズ，インコーポレイテッド 増量ガンマ−リノレン酸を含むベニバナ
EP3238543B1 (en) 2005-06-07 2019-03-20 DSM Nutritional Products AG Eukaryotic microorganisms for producing lipids and antioxidants
EP1991047B1 (en) 2006-03-01 2012-09-26 Pioneer Hi-Bred International Inc. Compositions related to the quantitative trait locus 6 (qtl6) in maize and methods of use
US7465793B2 (en) 2006-04-20 2008-12-16 E.I. Du Pont De Nemours And Company Synthetic Δ17 desaturase derived from Phytophthora ramourum and its use in making polyunsaturated fatty acids
CA2659603C (en) * 2006-08-01 2017-03-07 Ocean Nutrition Canada Limited Oil producing microbes and methods of modification thereof
EP2059588A4 (en) 2006-08-29 2010-07-28 Commw Scient Ind Res Org FATTY ACID SYNTHESIS
AU2007314481B2 (en) * 2006-10-30 2012-11-29 E. I. Du Pont De Nemours And Company Delta17 desaturase and its use in making polyunsaturated fatty acids
US7943365B2 (en) * 2007-05-03 2011-05-17 E.I. Du Pont De Nemours And Company Δ-5 desaturases and their use in making polyunsaturated fatty acids
JP2010533003A (ja) * 2007-07-13 2010-10-21 オーシャン ニュートリッション カナダ リミテッド Ｄ４デサチュラーゼ及びｄ５エロンガーゼ
EP2304032A1 (en) * 2008-08-01 2011-04-06 E. I. du Pont de Nemours and Company 6 desaturases and their use in making polyunsaturated fatty acids
DK2358882T3 (da) 2008-11-18 2017-11-06 Commw Scient Ind Res Org Enzymer og fremgangsmåder til fremstilling af omega-3 fedtsyrer
US8916154B2 (en) * 2009-04-27 2014-12-23 Abbott Laboratories Antibodies against delta-5 desaturase and uses thereof
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
KR102197208B1 (ko) 2012-06-15 2021-01-04 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 식물 세포에서 장쇄 다중불포화 지방산의 생성
ES2666895T3 (es) 2013-03-13 2018-05-08 Dsm Nutritional Products Ag Modificación genética de microorganismos
PE20170253A1 (es) 2013-12-18 2017-04-14 Nuseed Pty Ltd Lipido que comprende acidos grasos poliinsaturados de cadena larga
US10473585B2 (en) * 2014-06-16 2019-11-12 Murphy Brown, Llc Method and system for measuring a physical parameter of a particulate material
CA2953008C (en) 2014-06-27 2024-03-19 Nuseed Pty Ltd Lipid comprising docosapentaenoic acid
CN112741154A (zh) * 2019-10-30 2021-05-04 东北农业大学 一种早产儿配方液态乳及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5420034A (en) 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
US4943674A (en) 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
GB8507058D0 (en) 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8524276D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5004863B2 (en) 1986-12-03 2000-10-17 Agracetus Genetic engineering of cotton plants and lines
US5416011A (en) 1988-07-22 1995-05-16 Monsanto Company Method for soybean transformation and regeneration
US5130242A (en) 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
US5116871A (en) 1988-09-13 1992-05-26 Efamol Holdings Plc Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5106739A (en) 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5196198A (en) 1989-06-02 1993-03-23 Abbott Laboratories Parenteral nutrition product
US5175095A (en) 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
CA2083259C (en) 1990-05-25 2007-05-15 William D. Hitz Nucleotide sequence of soybean stearoyl-acp desaturase gene
US5518908A (en) 1991-09-23 1996-05-21 Monsanto Company Method of controlling insects
PH31293A (en) 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
DK0616644T3 (da) 1991-12-04 2003-10-27 Du Pont Fedtsyredesaturase-gener fra planter
US5912120A (en) 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
DK0668919T3 (da) 1992-11-17 2003-09-15 Du Pont Gener for mikorsomale delta-12-fedtsyredesaturaser og beslægtede enzymer fra planter
ATE193729T1 (de) 1993-02-26 2000-06-15 Calgene Llc Geminivirus-basiertes-genexpressionsystem
JPH07228888A (ja) 1994-02-17 1995-08-29 Shimadzu Corp 高度不飽和脂肪酸の精製方法
US5750176A (en) 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
NZ281041A (en) 1994-03-09 1998-04-27 Abbott Lab Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
JPH09509847A (ja) 1994-03-09 1997-10-07 アボツト・ラボラトリーズ 人乳化乳
US5427857A (en) * 1994-06-28 1995-06-27 E. I. Du Pont De Nemours And Company Cathodic electrocoating compositions containing branched epoxy amine resins
US5631152A (en) 1994-10-26 1997-05-20 Monsanto Company Rapid and efficient regeneration of transgenic plants
US5654402A (en) 1994-10-26 1997-08-05 Michigan State University Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase
JPH0913077A (ja) 1995-07-04 1997-01-14 Nisshin Oil Mills Ltd:The 臓器蓄積性の高い油脂
CA2285939C (en) * 1997-04-11 2010-06-15 Calgene Llc Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
US5972664A (en) * 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
AU4544799A (en) 1998-05-29 1999-12-13 Ohio University Compositions and methods for the synthesis of fatty acids, their derivatives and downstream products
JP2000069987A (ja) 1998-08-28 2000-03-07 Suntory Ltd アラキドン酸含有脂質並びにジホモ−γ−リノレン酸含有脂質の製造方法
WO2000020603A1 (en) 1998-10-05 2000-04-13 Abbott Laboratories Altered fatty acid biosynthesis in insect cells using delta five desaturase
EP1035207A1 (en) 1999-03-09 2000-09-13 MultiGene Biotech GmbH cDNA molecules of the members of gene family encoding human fatty acid desaturases and their use in diagnosis and therapy
PL357415A1 (en) 1999-06-07 2004-07-26 Basf Plant Science Gmbh Delta6-acetylenase and delta6-desaturase from ceratodon purpureus
DE60141760D1 (de) * 2000-09-28 2010-05-20 Bioriginal Food & Science Corp Fad4, fad5, fad5-2, and fad6, mitglieder der fettsäuredesaturasefamilie und ihre verwendungen
EP1392823B1 (en) 2001-01-25 2011-11-30 Abbott Laboratories Desaturase genes and uses thereof
US6635451B2 (en) 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof

Also Published As

Publication number Publication date
JP2008289490A (ja) 2008-12-04
CA2699611A1 (en) 2002-10-17
US8143486B2 (en) 2012-03-27
ATE535602T1 (de) 2011-12-15
EP2333052B1 (en) 2013-10-09
US20110003360A1 (en) 2011-01-06
JP4347400B2 (ja) 2009-10-21
US20090265798A1 (en) 2009-10-22
JP2008289479A (ja) 2008-12-04
EP2325300A1 (en) 2011-05-25
US7067285B2 (en) 2006-06-27
US20030190733A1 (en) 2003-10-09
JP4347397B2 (ja) 2009-10-21
US20110003351A1 (en) 2011-01-06
ES2377198T3 (es) 2012-03-23
CA2699611C (en) 2013-12-10
JP2008289491A (ja) 2008-12-04
EP2333052A1 (en) 2011-06-15
US20030167525A1 (en) 2003-09-04
CA2698579C (en) 2013-12-10
PT1392823E (pt) 2012-03-08
US20030157144A1 (en) 2003-08-21
US8143383B2 (en) 2012-03-27
US7241619B2 (en) 2007-07-10
EP2325300B1 (en) 2013-11-06
JP4347399B2 (ja) 2009-10-21
US6635451B2 (en) 2003-10-21
CA2698579A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
AR035534A1 (es) Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion
AU2018204726A1 (en) Production of dihydrosterculic acid and derivatives thereof
US9222101B2 (en) Method of producing fatty acids or lipids containing fatty acids using thioesterase variants
Faure et al. Camelina, a Swiss knife for plant lipid biotechnology
RU2008149700A (ru) Дельта-5-десатураза и ее применение для получения полиненасыщенных жирных кислот
CA2435685A1 (en) Desaturase genes and uses thereof
JP2013509178A5 (es)
JP6319889B2 (ja) アシル−ａｃｐチオエステラーゼ改変体を用いた脂質の製造方法
Yoshino et al. Production of ω3 fatty acids in marine cyanobacterium Synechococcus sp. strain NKBG 15041c via genetic engineering
Wang et al. Heterogeneous expression of human PNPLA3 triggers algal lipid accumulation and lipid droplet enlargement
Chi et al. Fatty acid biosynthesis in eukaryotic photosynthetic microalgae: identification of a microsomal delta 12 desaturase in Chlamydomonas reinhardtii
JP2014527803A (ja) トリアシルグリセロール（ｔａｇ）リパーゼの遺伝子操作による微細藻類における脂質含量の増大
Südfeld et al. Expression of glycerol-3-phosphate acyltransferase increases non-polar lipid accumulation in Nannochloropsis oceanica
Huang et al. Cloning and functional identification of delta5 fatty acid desaturase gene and its 5′-upstream region from marine fungus Thraustochytrium sp. FJN-10
AU2015356285A1 (en) Method of producing lipid using acyl-acp thioesterase
Chodok et al. Metabolic engineering and oil supplementation of Physcomitrella patens for activation of C 22 polyunsaturated fatty acid production
RU2011114558A (ru) Гены δ-8-десатуразы, ферменты, кодируемые ими, и их применение
CN104662154A (zh) 使用硫酯酶变异体的脂质的制造方法
Chenarani et al. Characterization of sucrose binding protein as a seed-specific promoter in transgenic tobacco Nicotiana tabacum L.
Aziz et al. Phosphate-induced changes in fatty acid biosynthesis in Chlorella sp. KS-MA2 strain
Thanasomboon et al. Construction of synthetic Escherichia coli producing s-linalool
Sharma et al. Genetic engineering in improving the output of algal biorefinery
US20240254500A1 (en) Increasing the accumulation of epa and dha in recombinant camelina
CN109477060A (zh) 增加tag产量的修饰藻类
AU2017322897A1 (en) Method of producing lipid

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure